Walker Marlan D 4/A

4/A · TherapeuticsMD, Inc. · Filed May 4, 2023

Form 4/AAmended

Period: 2023-04-12

Chief Executive Officer

Transactions

Exercise/Conversion
Common Stock
2023-04-26+1,010→ 14,041 total
Exercise/Conversion
Common Stock
2023-04-26+1,734→ 12,307 total
Sale
Common Stock
2023-04-26$3.64/sh−692$2,518→ 11,615 total
Exercise/Conversion
Restricted Stock Units
2023-04-26−1,010→ 0 total
Exercise: $0.00→ Common Stock (1,010 underlying)
Exercise/Conversion
Restricted Stock Units
2023-04-26−1,734→ 3,466 total
Exercise: $0.00→ Common Stock (1,734 underlying)

Footnotes (4)

[F1]The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date. The restricted stock units settled on April 26, 2023.
[F2]The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
[F3]Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023.
[F4]Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.

Documents

1 file